Key result
Patient partnership in cardiovascular trials may improve trial efficiency and measure patient-valued outcomes.
Answers are grounded in this paper and cite their sources.
Patient partnerships in cardiovascular therapeutic development may improve trial efficiency and ensure outcomes of value to patients are measured.
Patients are ultimately the end-users of medical therapies and need to be actively integrated as contributors and decision-makers in the process of product development throughout product lifecycles. This is increasingly being recognized by patients, investigators, regulators, payers, sponsors, and medical journals. However, cardiovascular research remains behind other fields in terms of the extent of patient involvement and awareness of clinical trials in cardiovascular research. True patient partnerships in cardiovascular therapeutic development may permit more rapid recognition of unmet needs, ensure alignment of product development priorities with patient priorities, improve efficiency of trials (e.g. recruitment), and ensure outcomes of value to patients are being measured in trials (e.g. quality of life). This paper reviews ongoing initiatives and remaining opportunities to accomplish contributive patient involvement in cardiovascular clinical research.
No takes yet. Share an insight, caveat, or question.
Zannad et al. (2021) conducted a review in Cardiovascular disease. Patient partnership in clinical trials was evaluated. Patient partnership in cardiovascular therapeutic development may improve trial efficiency, align priorities, and ensure outcomes of value to patients are measured.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: